regorafenib
bayer
[]
combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/gej cancer, a phase 3 study suggests. presented #gi23. #stcsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.